Osteoporosis: The need for comprehensive treatment guidelines

Clinical Therapeutics

Volumn 18, Issue 1, 1996, Pages 127-149

  Abbott III, Thomas A ^a,b   Lawrence, Bryan J ^b   Wallach, Stanley ^c  

^a RUTGERS UNIVERSITY   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; GROWTH HORMONE; PARATHYROID HORMONE DERIVATIVE; RALOXIFENE; SALCATONIN; SOMATOMEDIN C; TAMOXIFEN;

CLINICAL TRIAL; COST; COST EFFECTIVENESS ANALYSIS; DIET; ECONOMIC ASPECT; EXERCISE; FEMALE; FOOD AND DRUG ADMINISTRATION; FRACTURE; HORMONE SUBSTITUTION; HUMAN; MALE; MEDICAL CARE; MORBIDITY; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; UNITED STATES; VOMITING;

EID: 0029848807     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80186-X     Document Type: Article

References (106)

1. Lukert BP. Osteoporosis: Prevention and treatment. Compr Ther. 1990;16:36-42.
2. Office of Medical Applications Research. Osteoporosis: Consensus Conference. JAMA. 1984;252:799-802.
3. Osteoporosis. In: Berg RL, Cassells LS, eds. The Second Fifty Years: Promoting Health and Preventing Disability. Washington, DC: National Academy Press; 1990:76-100.
4. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
5. Heidrich F, Thompson RS. Osteoporosis prevention: Strategies applicable for general population groups. J Fam Pract. 1987; 25:33-39.
6. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7:178-208.
7. Melton LJ III. Epidemiology of fractures. In: Riggs BL, Melton LJ III, eds. Osteoporosis: Etiology, Diagnosis, and Management. New York: Raven Press; 1988:133-154.
8. Melton LJ III, Eddy DM, Johnson CC Jr. Screening for osteoporosis. Ann Intern Med. 1990;112:516-528.
9. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. NEJM. 1992;327:620-627.
10. Miller CW. Survival and ambulation following hip fracture. J Bone Jt Surg. 1978; 60A:930-934.
11. Kenzora JE, McCarthy RE, Lowell JD, et al. Hip fracture mortality: Relation to age, treatment, preoperative illness, time of surgery, and complications, Clin Orthop Relat Res. 1984;186:45-56.
12. Melton LJ III, Riggs BJ. Epidemiology of age-related fractures. In: Avioli LV, ed. The Osteoporotic Syndrome. New York: Grune & Stratton Inc; 1987:1-30.
13. White BL, Fisher WD, Laurin CA. Rate of mortality for elderly patients after fracture of the hip in the 1980's. J Bone Jt Surg. 1987;69A:1335-1340.
14. Frost HM. Clinical management of the symptomatic osteoporotic patient. Orthop Clin North Am. 1981;12:671-681.
15. Riggs BL. Practical management of the patient with osteoporosis. In: Riggs BL, Melton LJ III, eds. Osteoporosis: Etiology. Diagnosis, and Management. New York: Raven Press; 1988:481-490.
16. Cummings SR, Rubin SM, Black DM. The future of hip fractures in the United States: Numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop Relat Res. 1990;252:163-166.
17. Ross PD, Wasnich RD, Davis JW. Fracture prediction models for osteoporosis prevention. Bone. 1990;11:327-331.
18. Avioli LV. Socio-economic costs of osteoporosis and changing patterns. Ann Chir Gynaecol. 1988;77:224-228.
19. Reginster JY, Denis D, Deroisy R, et al. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res. 1994;9:69-73.
20. Parfitt AM, Duncan H. Metabolic bone disease affecting the spine. In: Rothman RH, Simeone FA, eds. The Spine. Philadelphia: WB Saunders; 1982:775-905.
21. Riggs BL, Wahner HW, Seeman E, et al. Changes in bone mineral density of the proximal femur and spine with aging. J Clin Invest. 1982;70:716-723.
22. Parfitt AM. Bone remodeling: Relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures. In: Riggs BL, Melton LJ III, eds. Osteoporosis: Etiology, Diagnosis, and Management. New York: Raven Press; 1988:45-93.
23. Riggs BL. Overview of osteoporosis. West J Med. 1991;154:63-77.
24. Recker RR. Current therapy for osteoporosis. J Clin Endocrinol Metab. 1993;76: 14-16.
25. Wasnich RD. Screening for osteoporosis: Pro. In: Genant HK, ed. Osteoporosis Update 1987. 1987:123-127.
26. Ross PD, Heilbrun LK, Wasnich RD, et al. Perspectives: Methodologic issues in evaluating risk factors for osteoporotic fractures. J Bone Miner Res. 1989;4: 649-656.
27. Ross PD, Wasnich RD, Vogel JM. Detection of prefracture spinal osteoporosis using bone mineral absorptiometry. J Bone Miner Res. 1988;3:1-11.
28. Johnston CC, Longcope C. Perimenopausal bone loss - a risk factor for osteoporosis. NEJM. 1990;323:1271-1273.
29. Riggs BL, Melton LJ III. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med. 1983;76:899-901.
30. Riggs BL, Melton LJ III. Involutional osteoporosis. NEJM. 1986;314:1676-1684.
31. Riggs BL, Melton LJ III. Clinical heterogeneity of involutional osteoporosis: Implications for preventive therapy. J Clin Endocrinol Metab. 1990;70:1229-1232.
32. Johnston CC Jr, Slemenda CW, Melton LJ III. Clinical use of bone densitometry. NEJM. 1991;324:1105-1109.
33. Melton LJ III, Kan SH, Frye MA, et al. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129: 1000-1011.
34. Brody JA, Farmer ME, White LR. Absence of menopausal effect on hip fracture occurrence in white females. Am J Public Health. 1984;74:1397-1398.
35. US Congress. Office of Technology Assessment. Hip Fracture Outcomes in People Age 50 and Over - Background Paper. OTA-BP-H-120. Washington, DC: US Government Printing Office; July 1994.
36. Holbrook TL, Grazier K, Kelsey JL, et al. Frequency of Occurrence, Impact and Cost of Selected Musculoskeletal Conditions in the United States. Chicago: Academy of Orthopedic Surgeons; 1984.
37. Garraway WM, Stauffer RN, Kurland LT, et al. Limb fractures in a defined population. II. Orthopedic treatment and utilization of health care. Mayo Clin Proc. 1979;54:708-713.
38. Weinstein MC. Estrogen use in postmenopausal women - costs, risks and benefits. NEJM. 1980;303:308-316.
39. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip. Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989;149:2445-2448.
40. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pain and disability associated with new vertebral fractures and other spinal conditions. J Clin Epidemiol. 1994; 47:231-239.
41. National Osteoporosis Foundation Scientific Advisory Board. Clinical indications for hone mass measurement. J Bone Miner Res. 1989;4(Suppl 2):1-28.
42. Cummings SR, Black DM. Should perimenopausal women be screened for osleoporosis? Ann Intern Med. 1986;104: 817-823.
43. Cook DJ, Guyatt GH, Adachi JD, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum. 1993;36:750-756.
44. Leidig G, Minne HW, Sauer P, et al. A study of complaints and their relation to vertebral destruction in patients with osteoporosis. Bone Miner. 1990;8:217-229.
45. Lukert BP. Vertebral compression fractures: How to manage pain, avoid disability. Geriatrics. 1994;49:22-26.
46. Melton LJ III, O'Fallon WM, Riggs BL. Secular trends in the incidence of hip fractures. Calcif Tissue Int. 1987;41:57-64.
47. Nordin BEC, Need AG, Chatterton BE, et al. Bone density screening for osteoporosis. Lancet. 1990;336:1327-1328.
48. Wallach S, Farley JR, Baylink DJ, et al. Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int. 1993;52:335-339.
49. Wolman RL. Osteoporosis and exercise. BMJ. 1994;309:400-403.
50. Pocock NA, Eisman JA, Yeates MG, et al. Physical fitness is a major determinant of femoral neck and lumbar spine bone mineral density. J Clin Invest. 1986;78: 618-621.
51. Kelly PJ, Eisman JHA, Sambrook PN. Interaction of genetic and environmental influences on peak bone density. Osteoporosis Int. 1990;1:56-60.
52. Dalsky GP, Stocke KS, Ehsani AA, et al. Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med. 1988;108:824-828.
53. Murphy S, Khaw KT, May H, Compton JE. Milk consumption and bone mineral density in middle aged and elderly women. BMJ. 1994;308:939-941.
54. Recker RR, Davies M, Hinders SM, et al. Bone gain in young adult women. JAMA. 1992;268:2403-2408.
55. Sentipal JM, Wardlaw GM, Mahan J, et al. Influence of calcium intake and growth indexes on vertebral bone mineral density in young females. Am J Clin Nutr. 1991;54:425-428.
56. Matkovic V, Kostial K, Simonovic I, et al. Bone status and fracture rates in two regions of Yugoslavia. Am J Clin Nutr. 1979;32:540-549.
57. More than hot flushes. Lancet. 1991;338: 917-918. Editorial.
58. Genent HK, Baylink DJ, Gallagher JC. Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol. 1989;161(No. 6, Pt 2):1842-1846.
59. Notelovitz M. Estrogen replacement therapy: Indications, contraindications and agent selection. Am J Obstet Gynecol. 1989;161(No. 6, Pt 2):1832-1841.
60. Elstein AS, Holzman GB, Ravitch MM, et al. Comparison of physician's decisions regarding estrogen replacement therapy for menopausal women and decisions derived from a decision analytic model. Am J Med. 1986;80:246-258.
61. Tosteson ANA, Rosenthal DI, Melton LJ III, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy. Ann Intern Med. 1990;113:594-603.
62. Tosteson ANA. Hormone replacement therapy: Benefit, risk and cost considerations. J Clin Pharmacol. 1994;34: 719-722.
63. Young RL, Kumar NS, Goldzieher JW. Management of menopause when estrogen therapy cannot be used. Drugs. 1990;40:220-230.
64. Cauley JA, Cummings SR, Black DM, et al. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 1990; 163:1438-1444.
65. Barlow DH, Brockie JA, Rees CMP, et al. Study of general practice consultations and menopausal problems. BMJ. 1991;302:274-276.
66. Reginster JY, Denis D, Albert A, et al. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet. 1987; 1481-1483.
67. Chesnut CH III. Drug therapy: Calcitonin, bisphosphonates, anabolic steroids, and hPTH(1-34). In: Riggs BL, Melton LJ III, eds. Osteoporosis: Etiology, Diagnosis, and Management. New York: Raven Press; 1988:403-414.
68. McDermott MT, Kidd GS. The role of calcitonin in the development and treatment of osteoporosis. Endocr Rev. 1987;8: 377-390.
69. Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989;11:205-209.
70. Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol. 1985;3:155-157.
71. Wimalawansa SJ. Long- and short-term side effects and safety of calcitonin in man: A prospective study. Calcif Tissue Int. 1993;52:90-93.
72. Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol. 1989;30:435-442.
73. Overgaard K, Hansen MA, Jensen SB, et al. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ. 1992;305:556-561.
74. Overgaard K, Lindsay R, Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: A subanalysis of a 2-year study. Clin Ther. 1995;17:680-685.
75. Overgaard K, Riis BJ. Nasal calcitonin in osteoporosis. Calcif Tissue Int. 1994;55: 79-81.
76. Reginster JY, Denis D, Albert A, Franchimont P. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (ssct) by comparison with intramuscular (im) or placebo injection in normal subjects. Bone Miner. 1987;2: 133-140.
77. MacIntyre I, Stevenson JC, Whitehead MI, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet. 1988;8591: 900-902.
78. Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest. 1994;24: 656-659.
79. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med. 1993;95(Suppl 5A):48S-52S.
80. Licata AA. Prevention and osteoporosis management. Clevel Clin J Med. 1994; 61:451-459.
81. Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease: Clinical pharmacology and therapeutic use. Drugs. 1993;46:594-617.
82. Licata AA. From bathtub ring to osteoporosis: A clinical review of the bisphosphonates. Clevel Clin J Med. 1993;60: 284-290.
83. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM. 1990;322:1265-1271.
84. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. NEJM. 1990;323:73-79.
85. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99: 144-152.
86. Rossini M, Gatti D, Zamberlan N, et al. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 1994;9: 1833-1837.
87. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 1993;76:1399-1406.
88. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. NEJM. 1995;333:1437-1443.
89. Eisman JA, Christiansen C, McClung M, et al. Alendronate prevents bone loss at the spine and hip in recently postmenopausal women. J Bone Miner Res. 1995;10(Suppl 1 ):S176. Abstract.
90. Recker RR, Karpf DB, Quan H, et al. Three-year treatment of osteoporosis with alendronate: Effect on vertebral fractures incidence. Washington, DC: Endocrine Society; 1995. Abstract #OR2-5.
91. Shapiro DR, Thompson DE, Karpf DB, et al. Non-vertebral fracture incidence in patients treated with alendronate. J Bone Miner Res. 1995;10(Suppl 1):S176. Abstract.
92. Carter DR, Beaupre GS. Effects of fluoride treatment on bone strength. J Bone Miner Res. 1990;5(Suppl 1):S177-S184.
93. Pak CYC, Zerwekh JE, Sakhaee K, et al. Slow-release NaF is effective and safe in postmenopausal osteoporosis. J Bone Miner Res. 1995;10(Suppl 1):S139. Abstract.
94. Pak CYC, Zerwekh JE, Sakhaee K, et al. Slow-release NaF virtually eliminates spinal fractures in postmenopausal women with mild-moderate bone loss. J Bone Miner Res. 1995; 10(Suppl 1):S153. Abstract.
95. 3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism. 1990;39 (Suppl 1):30-34.
96. Tilyard MW, Spears GFS, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. NEJM. 1992;326:357-362.
97. White CP, Morrison NA, Gardiner EM, et al. Vitamin D receptor alleles and bone physiology. J Cell Biochem. 1994;56: 307-314.
98. Grisso JA, Baum CR, Turner BJ. What do physicians in practice do to prevent osteoporosis? J Bone Miner Res. 1990;5: 213-219.
99. US Congress. Office of Technology Assessment. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Washington, DC: US Government Printing Office; 1995.
100. Rubin SM, Cummings SR. The impact of bone densitometry on women's use of measures to prevent fractures. In: Christiansen C, Overgaard K, eds. Osteoporosis. Third International Symposium on Osteoporosis, Copenhagen, Denmark, October 14-20, 1990. 1990:1125-1126.
101. Ott S. Should women get screening bone mass measurements? Ann Intern Med. 1986;104:874-876.
102. Hall FM, Davis MA, Baran DT. Bone mineral screening for osteoporosis. NEJM. 1987;316:212-214.
103. Wasnich RD, Hagino R, Ross PD. Osteoporosis: Will the use of new technology increase or decrease health care costs? Hawaii Med J. 1987;46:199-200.
104. Riggs BL, Wahner HW. Bone densitometry and clinical decision-making in osteoporosis. Ann Intern Med. 1988;108: 293-295.
105. Greendale GA, Silverman SL, Hays RD, et al. Health-related quality of life in osteoporosis clinical trials. Calcif Tissue Int. 1993;53:75-77.
106. Doud DK, Meredith KE, Fassett MJ, et al. Assessment of functional disability and quality of life in patients with osteoporosis. Arthritis Rheum. 1992;35(Suppl 9):S129. Abstract.